EctoATPase (EC [3.6.1.3]) is a key enzyme in the enzymatic cascade of ATP hydrolysis to adenosine [1] . There is convincing evidence that ectoATPase plays the role of an enzyme controlling the ATP interaction with Pz-purinoceptors [2], similar to the role of cholinesterase in the cholinergic synapse.
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pressing the ectoATPase activity in various tissues [2, 9] . Previously [13, 14] we have established that some of the PPADS derivatives also exhibit antagonism with respect to P2-purine receptors. The purpose of this work was to assess the effect of some new PPADS analogs on the ectoATPase activity.
METHODS OF INVESTIGATION
The experiments were performed with the muscle tissues 350 -550 g of mongrel male guinea pigs killed by impact on the head and dehematization. The muscle tissue samples were prepared from urinary bladders, deferent ducts, and taeniae caeci as described in [13] . The ectoATPase activity was determined at 37 + I~ in a buffer containing 100 mM 4-(2-hydroxyethyl)-1 -piperazine-ethanesul fonic acid (HEPES), 135 mM NaC1, 5 mM KC1, 2 mM CaC12, 2 mM MgC12, and 10 mM glucose (pH 7.4). Smooth muscle pieces (2 -3 mg) were placed in a special 24-cell unit and washed for 15 min in the buffer to remove nucleotides and damaged cells. Then the washing buffer was removed and the samples were incubated for 10 + 1 min in a buffer containing ATP at a concentration of 300 mM. To stop the enzymatic reaction, the buffer was removed from the cell and frozen. After that, the samples were washed again and incubated for 10 + 1 min in the ATP-containing buffer to which the substance to be tested was added at a concentration of 10 gM.
The concentration of unhydrolyzed ATP was determined by HPLC. The analyses were performed using a Spherisorb (Hichrom, UK) column with an SPD-10A injector, linked to a LC-10AS spectrophotometer (Shimadzu, Japan). The column was preliminarily washed for 24 h with a mobile phase (0.2M KHzPO4+3% methanol, pH6.0) at a rate of 0.2 ml/min. The nucleotide separation was effected with the mobile phase flowing at a rate of 1.5 ml/min and detected at a wavelength of 260 nm using a recorder velocity of 0091-150X/00/3405-0226525.00 9 2000 Kluwer Academic/Plenum Publishers 1 cm/min; the sample volume was 20 ~tl. Under these experimental conditions, nucleotides were eluted in the following order: ATE ADP, AMP. The ATP content was evaluated by comparing the corresponding peak heights for the sample and a standard ATP preparation. The enzyme activity was expressed in nmole/mg tissue/min. The effect of each substance studied was assessed by comparing the enzymatic reaction rates in the samples with and without the additive.
The experimental data were statistically processed by method of direct differences and presented in the M+ m form using the results of at least two independent measurements in four parallel runs.
ATP and HEPES were purchased from Sigma (USA 
RESULTS AND DISCUSSION
We have studied a total of 27 compounds. Reliable drug-induced changes in the ectoATPase activity were observed for 13 substances (Table 1) . Most of these, producing various effects upon ectoATPase, also influenced P2-purine receptors as was demonstrated previously [13, 14] , while compounds I, V, XVII, and XXV selectively changed only the enzyme activity. Compound I, producing a 10% increase in the activity of ectoATPase in taenia caeci, inhibited P2v-purinoceptors in this tissue when taken at a greater concentration (30 ~M) [13] .
Compound V produced a 16% inhibition in the ectoATPase activity in taenia caeci, while compounds XVII and XXV inhibited the enzyme activity in the urinary bladder muscles (by 19 and 11%, respectively). However, these compounds cannot be used as ectoATPase inhibitors since the decrease in the enzyme activity never exceeds 20%. Moreover, compounds V and XVII (but not XXV) taken at a concentration of 30 pM reliably inhibit P2-purine receptors in both tissues (taenia caeci and urinary bladder) [13] . A special group includes nine compounds acting on both Pz-purine receptors and ectoATPase. The effect upon receptors does not allow these substances to be considered as selective ectoATPase inhibitors. The effect upon purine receptors is most probably also distorted by the action upon ectoATPase. Compounds V, IX, XVI, and XXI stimulate the ectoATPase activity in the muscles of deferent ducts, while compounds I, IV, XVII, XV, and XXI-in the muscles of taenia caeci (Table 1 ). This may account for a pronounced antagonist effect observed in the pharmacological experiments with Pz-purine receptors. On the other hand, the ectoATPase inhibition observed for compounds IV, V, VIII, IX, XIII, XV, XVII, XI, and XXIV can probably mask their blocking action upon purine receptors in the corresponding tissues.
Of the 27 compounds studied, 14 exhibited no reliable action upon the ectoATPase activity in either of the tissues studied. It should be noted that compounds III and VII, previously characterized as promising selective antagonists of Pz-purine receptors [2, 13] , produced no effect upon the enzyme. This result confirms our recommendations conceming the expediency of using these compounds as selective antagonists of P2-purine receptors in physiological and pharmacological experiments in vitro.
Thus, the results of our experiments showed that 9 new PPADS derivatives exert a certain influence on the ectoATPase activity, which hinders correct interpretation of their effects upon P2-purine receptors. It would be of interest to study the behavior of the ectoATPase activity under the action of some structural analogs of compound XXV, which may be promising inhibitors of ectoATPase. Compounds III and VII, previously characterized as selective antagonists of Pz-purine receptors, do not affect the ectoATPase activity.
